Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 10/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251481 | 0.82 | MTOR (0.52) | MTORLRRK2PIK3C3 | |
| SCHEMBL249782 | 0.82 | MTOR (0.52) | MTORLRRK2PIK3C3 | |
| SCHEMBL249781 | 0.82 | MTOR (0.52) | MTORLRRK2PIK3C3 | |
| SCHEMBL14087877 | 0.79 | PIK3C3 (0.48) | MTORPIK3C3 | |
| SCHEMBL2599611 | 0.79 | PIK3C3 (0.48) | MTORPIK3C3ATRPIK3CD | |
| SCHEMBL2599609 | 0.79 | PIK3C3 (0.48) | MTORPIK3C3ATRPIK3CD | |
| SCHEMBL16388496 | 0.79 | PIK3C3 (0.48) | PIK3C3ATRPIK3CD | |
| SCHEMBL16388748 | 0.79 | PIK3C3 (0.48) | PIK3C3ATRPIK3CD | |
| SCHEMBL14087747 | 0.79 | PIK3C3 (0.48) | MTORPIK3C3 | |
| SCHEMBL2599663 | 0.79 | PIK3C3 (0.48) | MTORPIK3C3ATRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | NIH-DEITR | 2013-08-08 | — | — | US | claimed |
| EP-2571858-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | Research Triangle Institute (US) | 2013-03-27 | — | — | EP | claimed |
| WO-2011146850-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | claimed |
| EP-2571858-B1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RES TRIANGLE INST (US) | 2018-06-20 | — | — | EP | disclosed |
| US-9617229-B2 | Phenylmorpholines and analogues thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | NIH-DEITR | 2013-08-08 | — | — | US | disclosed |
| EP-2571858-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | Research Triangle Institute (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146850-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203752-A1 | PHENYLMORPHOLINES AND ANALOGUES THEREOF | PNMT, OPRL1, OPRM1 | MTOR 2418/4885LRRK2 652/4885DRD2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.